Intra Cellular Therapies | ITCI - Selling And Administration Expenses

Intra Cellular Therapies reported $94.63M in Selling and Administration Expenses for its fourth fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Selling And Administration Expenses Change
Acadia Pharmaceuticals ACAD:US USD 104.4M 26.29M
ALKERMES ALKS:US USD 157.54M 4.76M
Aptinyx Inc APTX:US USD 4.65M 547K
Biocryst Pharmaceuticals BCRX:US USD 50.15M 13.23M
Biogen BIIB:US USD 632.8M 69.5M
Bristol Myers Squibb BMY:US USD 2.27B 336M
Cytokinetics CYTK:US USD 53.97M 5.75M
Esperion Therapeutics ESPR:US USD 24.14M 816K
Gilead Sciences GILD:US USD 2.02B 807M
Halozyme Therapeutics HALO:US USD 36.35M 2.28M
Intra Cellular Therapies ITCI:US USD 94.63M 6.26M
JAZZ PHA JAZZ:US USD 383.2M 65.52M
Johnson & Johnson JNJ:US USD 6.51B 423M
Marinus Pharmaceuticals MRNS:US USD 14.66M 1.27M
Minerva Neurosciences NERV:US USD 1.88M 959.93K
Nektar Therapeutics NKTR:US USD 21.94M 595K
Neurocrine Biosciences NBIX:US USD 182.9M 3.4M
Novartis NVS:US USD 3.7B 295M
Prothena PRTA:US USD 13.12M 1.14M
Supernus Pharmaceuticals SUPN:US USD 73.97M 38.34M
United Therapeutics UTHR:US USD 152M 53.6M
Vanda Pharmaceuticals VNDA:US USD 32.78M 2.93M